

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
廣川 誠	赤芽球癆	日本血液学会	血液専門医テキスト改訂第2版	南江堂	東京	2015	196-198
廣川 誠	赤芽球癆	山口徹・北原光夫	今日の治療指針2015	医学書院	東京	2015	650-651
廣川 誠	赤芽球癆	金倉讓	最新ガイドライン準拠血液疾患診断・治療指針	中山書店	東京	2015	214-218
廣川 誠	慢性赤芽球癆の診断と治療	松田晃	ブラッシュアップ骨髄不全症	中外医学社	東京	2015	74-85
廣川 誠, 澤田賢一	赤芽球癆	吉田彌太郎	診療の手引きと臨床データ集 血液疾患診療ハンドブック改訂3版	医療ジャーナル社	大阪	2015	59-69
廣川 誠, 澤田賢一	血液腫瘍と止血・血栓	鈴木 重統ほか	止血・血栓ハンドブック	西村書店	東京	2015	145-147
廣川 誠, 澤田賢一	赤芽球癆		免疫症候群 第2版 -その他の免疫疾患を含めて-	日本臨牀社	大阪	2015	325-330
長尾貴代, 守時由起, 廣川 誠	悪性貧血		免疫症候群 第2版 -その他の免疫疾患を含めて-	日本臨牀社	大阪	2015	277-280
川端浩, 高折晃史	特発性造血障害調査研究班による症例登録と中央診断の現状	朝長万左男	骨髄異形成症候群 (MDS) の基礎と臨床 改訂版	医薬ジャーナル社	大阪市	2015	160-169

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Nagai S.and Ozawa K.	New Japanese regulatory frameworks for clinical research and marketing authorization of gene therapy and cellular therapy products.	Curr Gene Ther			In press
Nagai S.and Ozawa K.	Comprehensive analysis of clinical development and regulatory submission promotion schemes for oncologic drugs as the Japanese national projects.	Invest New Drugs	34	777-91	2016
Ninomiya H, Obara N, Chiba S, Usuki K, Nishiwaki K, Matsumura I, Shichishima T, Okamoto S, Nishimura JI, Ohyashiki K, Nakao S, Ando K, Kanda Y, Kawaguchi T, Nakakuma H, Harada D, Akiyama H, Kinoshita T, Ozawa K, Omine M, and Kanakura Y.	Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan.	Int. J. Hematol.	104	548-58	2016

Zaimoku Y, Takamatsu H, Hosomichi K, Ozawa T, Nakagawa N, Imi T, Maruyama H, Katagiri T, Kishi H, Tajima A, Muraguchi A, Kashiwase K, and Nakao S	Identification of an HLA class I allele closely involved in the autoantigen presentation in acquired aplastic anemia.	Blood	129	2908-16	2017
Nakao S, and Ishiyama K	Hypomegakaryocytic thrombocytopenia and increased number of PNH-phenotype cells - an emerging subgroup of myelodysplastic syndrome showing frequent response to immunosuppression.	Br J Haematol			In press
Gargiulo L, Zaimoku Y, Scappini B, Maruyama H, Ohumi R, Luzzatto L, Nakao S, and Notaro R	Glycosylphosphatidylinositol-specific T cells, IFN-gamma-producing T cells, and pathogenesis of idiopathic aplastic anemia.	Blood	129	388-92	2017
Espinoza JL, Kotecha R, and Nakao S	Microbe-Induced Inflammatory Signals Triggering Acquired Bone Marrow Failure Syndromes.	Front Immunol	8	186	2017

Elbadry MI, Espinoza JL, and Nakao S	Induced pluripotent stem cell technology: A window for studying the pathogenesis of acquired aplastic anemia and possible applications.	Exp Hematol.	49	9-18	2017
Tominaga R, Katagiri T, Kataoka K, Kataoka K, Wee RK, Maeda A, Gomyo H, Mizuno I, Murayama T, Ogawa S, and Nakao S	Paroxysmal nocturnal hemoglobinuria induced by the occurrence of BCR-ABL in a PIGA mutant hematopoietic progenitor cell.	Leukemia	30	1208-10	2016
Saito C, Ishiyama K, Yamazaki H, Zaimoku Y, and Nakao S	Hypomegakaryocytic thrombocytopenia (HMT): an immune-mediated bone marrow failure characterized by an increased number of PNH-phenotype cells and high plasma thrombopoietin levels.	Br J Haematol.	175	246-51	2016

Nakao S, and Gale RP	Are mild/moderate acquired idiopathic aplastic anaemia and low-risk myelodysplastic syndrome one or two diseases or both and how should it/they be treated?	Leukemia	30	2127-30	2016
Daitoku S, Takenaka K, Yamauchi T, Yurino A, Jinnouchi F, Nunomura T, Eto T, Kamimura T, Higuchi M, Harada N, Saito N, Miyamoto T, Iwasaki H, and Akashi K.	Calreticulin mutation does not contribute to disease progression in essential thrombocythemia by inhibiting phagocytosis.	Exp Hematol.	44	817-25	2016
Takenaka K, Shimoda K, Uchida N, Shimomura T, Nagafuji K, Kondo T, Shibayama H, Mori T, Usuki K, Azuma T, Tsutsumi Y, Tanaka J, Dairaku H, Matsuo K, Ozawa K, Kurokawa M, Arai S, and Akashi K.	Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan.	Int J Hematol.	105	59-69	2017

<p>Kawabata H, Tohyama K, Matsuda A, Araseki K, Hata T, Suzuki T, Kayano H, Shimbo K, Zaike Y, Usuki K, Chiba S, Ishikawa T, Arima N, Nogawa M, Ohta A, Miyazaki Y, Mitani K, Ozawa K, Arai S, Kurokawa M, and Takaori-Kondo A</p>	<p>Validation of the revised International Prognostic Scoring System in patients with myelodysplastic syndrome in Japan</p>	<p>Int J Hematol.</p>			<p>In press</p>
--	---	---------------------------	--	--	-----------------

<p>Pfeilstöcker M, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Levis A, Luebbert M, Maciejewski J, Machherndl-Spa ndl S, Magalhaes SM, Miyazaki Y, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, and Greenberg PL.</p>	<p>Time-dependent changes in mortality and transformation risk in MDS.</p>	<p>Blood</p>	<p>128</p>	<p>902-10</p>	<p>2016</p>
--	--	--------------	------------	---------------	-------------

<p>Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent</p>	<p>Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes.</p>	<p>Blood</p>	<p>128</p>	<p>2096-7</p>	<p>2016</p>
---	---	--------------	------------	---------------	-------------

<p>Muramatsu H, Okuno Y, Yoshida K, Shiraishi Y, Doisaki S, Narita A, Sakaguchi H, Kawashima N, Wang X, Xu Y, Chiba K, Tanaka H, Hama A, Sanada M, Takahashi Y, Kanno H, Yamaguchi H, Ohga S, Manabe A, Harigae H, Kunishima S, Ishii E, Kobayashi M, Koike K, Watanabe K, Ito E, Takata M, Yabe M, Ogawa S, Miyano S, Kojima S</p>	<p>Clinical utility of next-generation sequencing for bone marrow failure syndrome.</p>	<p>Genet Med.</p>			<p>In press</p>
<p>Elmahdi,S, Hama A, Manabe A, Hasegawa D, Muramatsu H, Narita A, Nishio N, Ismael O, Kawashima N, Okuno Y, Xu Y, Wang X, Takahashi Y, Ito M, and Kojima S</p>	<p>A cytokine-based diagnostic program in pediatric aplastic anemia and hypocellular refractory cytopenia of childhood. Pediatr Blood</p>	<p>Cancer</p>	<p>63</p>	<p>652-8</p>	<p>2016</p>

Kako S, Kanda Y, Kato J, Yamamoto W, Kato S, Onizuka M, Yokota A, Tataro R, Yokoyama H, Hagihara M, Usuki K, Gotoh M, Watanabe R, Kawai N, Saitoh T, Kanamori H, Takahashi S, and Okamoto S.	The bridge treatment selected at the decision for transplantation did not affect the outcomes in patients with MDS.	Hematol Oncol.			In press
Hayakawa J, Kanda J, Akahoshi Y, Harada N, Kameda K, Ugai T, Wada H, Ishihara Y, Kawamura K, Sakamoto K, Ashizawa M, Sato M, Terasako-Saito K, Kimura SI, Kikuchi M, Yamazaki R, Kako S, and Kanda Y.	Meta-analysis of treatment with rabbit and horse antithymocyte globulin for aplastic anemia.	Int J Hematol	105	578-86	2017
Nagai S.and Ozawa K.	Clinical trial designs to obtain marketing authorization of drugs for haematologic malignancy in Japan, the EU and the US	British Journal of Haematology	March 27, 2016 Epub		2016
Kitanaka, A., Takenaka, K., Shide, K., Miyamoto, T., Kondo, T., Ozawa, K., Kurokawa, M., Akashi, K., and Shimoda, K.	Splenic irradiation provides transient palliation for symptomatic splenomegaly associated with primary myelofibrosis: a report on 14 patients.	Int. J. Hematol.,	103(4)	423-438	2016

Muroi, K., Miyamura, K., Okada, M., Yamashita, T., Murata, M., Ishikawa, T., Uike, N., Hidaka, M., Kobayashi, R., Imamura, M., Tanaka, J., Ohashi, K., and Taniguchi, S.,	Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study.	Int. J. Hematol.	103(2)	243-250	2016
Onishi, A., kimoto, T., Urabe, M., Hirahara, I., Muto, S., Ozawa, K., Nagata, D., and Kusano, E	Attenuation of methylglyoxal-induced peritoneal fibrosis: immunomodulation by interleukin-10.	Lab. Invest.	95(12)	1353-1362	2015
Hirokawa, M., Sawada, K., Fujishima, N., Teramura, M., Bessho, M., Dan, K., Tsurumi, H., Nakao, S., Urabe, A., Fujisawa, S., Yonemura, Y., Kawano, F., Oshimi, K., Sugimoto, K., Matsuda, A., Karasawa, M., Arai, A., Komatsu, N., Harigae, H., Omine, M., Ozawa, K., Kurokawa, M. and PRCA Collaborative Study Group	Long-term outcome of patients with acquired chronic pure red cell aplasia (PRCA) following immunosuppressive therapy: a final report of the nationwide cohort study in 2004/2006 by the Japan PRCA collaborative study group.	Br. J. Haematol.	169(6)	879-886	2015

Suzuki, T., Oh, I., Ohmine, K., Meguro, A., Mori, M., Fujiwara, S., Yamamoto, C., Nagai, T., and Ozawa, K.	Distribution of serum erythropoietin levels in Japanese patients with myelodysplastic syndromes.	Int. J. Hematol.	101(1)	32-36	2015
Miyasaka N, Miura O, Kawaguchi T, Arima N, Morishita E, Usuki K, Morita Y, Nishiwaki K, Ninomiya H, Gotoh A, Imashuku S, Urabe A, Shichishima T, Nishimura JI, and Kanakura Y.	Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review.	Int J Hematol	Epub ahead of print		2016
Sasano T, Tomimatsu T, Nishimura J, Matsumura I, Kanakura Y, and Kimura T	Two consecutive pregnancies in a patient with paroxysmal nocturnal haemoglobinuria treated with anticoagulant therapy at different doses.	Blood Coagul Fibrinolysis	27(1)	109-112	2016

Inaguma Y, Akatsuka Y, Hosokawa K, Maruyama H, Okamoto A, Katagiri T, Shiraishi K, Murayama Y, Tsuzuki-Iba S, Mizutani Y, Nishii C, Yamamoto N, Demachi-Oka mura A, Kuzushima K, Ogawa S, Emi N, and Nakao S.	Induction of HLA-B*40:02-restricted T cells possessing cytotoxic and suppressive functions against haematopoietic progenitor cells from a patient with severe aplastic anaemia.	Br J Haematol	172	131-4	2016
Dao AT, Yamazaki H, Takamatsu H, Sugimori C, Katagiri T, Maruyama H, Zaimoku Y, Maruyama K, Ly TQ, Espinoza L, and Nakao S.	Cyclosporine restores hematopoietic function by compensating for decreased Tregs in patients with pure red cell aplasia and acquired aplastic anemia.	Ann Hematol	95	771-81	2016
Yoshizato T, Dumitriu B, Hosokawa K, Makishima H, Yoshida K, Townsley D, Sato-Otsubo A, Sato Y, Liu D, Suzuki H, Wu CO, Shiraishi Y, Clemente MJ, Kataoka K, Shiozawa Y, Okuno Y, Chiba K, Tanaka H, Nagata Y, Katagiri T, Kon A, Sanada M, Scheinberg P, Miyano S,	Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia.	N Engl J Med	373	35-47	2015

Maciejewski JP, Nakao S, Young NS, and Ogawa S.					
Tominaga R, Katagiri T, Kataoka K, Wee RK, Maeda A, Gomyo H, Mizuno I, Murayama T, Ogawa S, and Nakao S.	Paroxysmal nocturnal hemoglobinuria induced by the occurrence of BCR-ABL in a PIGA mutant hematopoietic progenitor cell.	Leukemia		1-3	2015
Sugimori N, Espinoza JL, Trung LQ, Takami A, Kondo Y, An DT, Sasaki M, Wakayama T, and Nakao S.	Paraptosis cell death induction by the thiamine analog benfotiamine in leukemia cells.	PLoS One	10	e0120709	2015
廣川 誠, 植木重治, 面川 歩	慢性炎症に伴う貧血における鉄代謝異常の分子機構	血液内科	70(3)	291-294	2015
廣川 誠	内科学と検査医学の融合を目指して	臨床病理	63(3)	392-396	2015
廣川 誠	赤芽球癆の診断と治療	臨床血液	56(10)	62-71	2015
廣川 誠, 藤島直仁, 面川 歩, 植木重治	再生不良性貧血と赤芽球癆の病態と治療	内科学会雑誌	104	1405-1412	2015

Konno, Y., Ueki, S., Takeda, M., Kobayashi, Y., Tamaki, M., Moritoki, Y., Oyamada, H., Itoga, M., Kayaba, H., Omokawa, A., and Hirokawa, M.	Functional analysis of free fatty acid receptor GPR120 in human eosinophils: implications in metabolic homeostasis.	PLoS One.	10(3)	e0120386	2015
Itoga, M., Konno, Y., Moritoki, Y., Saito, Y., Ito, W., Tamaki, M., Kobayashi, Y., Kayaba, H., Kikuchi, Y., Chihara, J., Takeda, M., Ueki, S., and Hirokawa, M.	G-Protein-Coupled Estrogen Receptor Agonist Suppresses Airway Inflammation in a Mouse Model of Asthma through IL-10.	PLoS One.	10(3)	e0123210	2015
Suehiro Y, Hasegawa A, Iino T, Sasada A, Watanabe N, Matsuoka M, Takamori A, Tanosaki R, Utsunomiya A, Choi I, Fukuda T, Miura O, Takaishi S, Teshima T, and Akashi K.	Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study	Br J Haematol	169	356-367	2015
Oritani K, Okamoto S, Tauchi T, Saito S, Ohishi K, Handa H, Takenaka K, Gopalakrishna P, Amagasaki T, Ito K, and Akashi K	A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis	Int J Hematol	101	295-304	2015

Yamasaki S, Yoshimoto G, Ogawa R, Aoki K, Higuchi M, Harada N, Arima F, Kondo S, Matubara F, Takahashi T, Uike N, Miyamoto T, Okamura S, Akashi K; for the Fukuoka Blood and Marrow	Factors prognostic of eligibility for allogeneic HCT among older patients with AML-CR1 and adverse- or intermediate-risk cytogenetics	Ann Hematol	94	1159-1165	2015
Uryu H, Hashimoto D, Kato K, Hayase E, Matsuoka S, Ogasawara R, Takahashi S, Maeda Y, Iwasaki H, Miyamoto T, Saijo S, Iwakura Y, Hill GR, Akashi K, and Teshima T	-Mannan induces Th17-mediated pulmonary graft-versus-host disease in mice	Blood	125	3014-3023	2015
Sugita J, Kawashima N, Fujisaki T, Kakihana K, Ota S, Matsuo K, Miyamoto T, Akashi K, Taniguchi S, Harada M, Teshima T; Japan Study Group for Cell Therapy and Transplantation	HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide after Busulfan-Containing Reduced-Intensity Conditioning	Biol Blood Marrow Transplant	21	1646-1652	2015

Kikushige Y, Miyamoto T, Yuda J, Jabbarzadeh-Tabrizi S, Shima T, Takayanagi S, Niiro H, Yurino A, Miyawaki K, Takenaka K, Iwasaki H, and Akashi K	A TIM-3/Gal-9 Autocrine Stimulatory Loop Drives Self-Renewal of Human Myeloid Leukemia Stem Cells and Leukemic Progression	Cell Stem Cell	17	341-352	2015
Hayashi M, Maehara K, Harada A, Semba Y, Kudo K, Takahashi H, Oki S, Meno C, Ichiyangi K, and Akashi K,	Chd5 Regulates MuERV-L/MERVL Expression in Mouse Embryonic Stem Cells Via H3K27me3 Modification and Histone H3.1/H3.2	J Cell Biochem	117	780-792	2015
Takashima S, Miyamoto T, Kamimura T, Yoshimoto G, Yoshida S, Henzan H, Takase K, Kato K, Ito Y, Ohno Y, Nagafuji K, Eto T, Teshima T, and Akashi K	Effects of conditioning intensity in allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia	Int J Hematol	102	689-696	2015

<p>Della Porta MG, Tuechler H, Malcovati L, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL, and Cazzola M.</p>	<p>Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)</p>	<p>Leukemia</p>	<p>29(7)</p>	<p>1502-1513</p>	<p>2015</p>
<p>Sugino N, Miura Y, Yao H, Iwasa M, Fujishiro A, Fujii S, Hirai H, Takaori-Kondo A, Ichinohe T, and Maekawa T</p>	<p>Early osteoinductive human bone marrow mesenchymal stromal/stem cells support an enhanced hematopoietic cell expansion with altered chemotaxis- and adhesion-related gene expression profiles.</p>	<p>Biochem Biophys Res Commun</p>	<p>469</p>	<p>823-829</p>	<p>2016</p>

Uchiyama T, Kawabata H, Miura Y, Yoshioka S, Iwasa M, Yao H, Sakamoto S, Fujimoto M, Haga H, Kadowaki N, Maekawa T, and Takaori-Kondo A	The role of growth differentiation factor 15 in the pathogenesis of primary myelofibrosis.	Cancer Med.	4	1558-1572	2015
Arai Y, Mizugishi K, Nonomura K, Naitoh K, Takaori-Kondo A, and Yamashita K	Phagocytosis by human monocytes is required for the secretion of presepsin.	J Infect Chemother	21	564-569	2015
Arai Y, Kondo T, Kitano T, Hishizawa M, Yamashita K, Kadowaki N, Yamamoto T, Yano I, Matsubara K, and Takaori-Kondo A	Monitoring mycophenolate mofetil is necessary for the effective prophylaxis of acute gvhd after cord blood transplantation.	Bone Marrow Transplant	50	312-314	2015
川端浩, 高折晃史	Mdsの診断と臨床像	最新医学	70	2114-2120	2015

<p>Kanda Y, Kobayashi T, Mori T, Tanaka M, Nakaseko C, Yokota A, Watanabe R, Kako S, Kakihara K, Kato J, Tanihara A, Doki N, Ashizawa M, Kimura SI, Kikuchi M, Kanamori H, and Okamoto S</p>	<p>A randomized controlled trial of cyclosporine and tacrolimus with strict control of blood concentrations after unrelated bone marrow transplantation.</p>	<p>Bone Marrow Transplant.</p>	<p>Jan 51(1)</p>	<p>103-9</p>	<p>2016</p>
<p>Motohasi K, Fujisawa S, Onizuka M, Kako S, Sakaida E, Shono K, Tatara R, Doki N, Mori T, Sakura T, Aotsuka N, Fuji E, Tomita N, Kawai N, Saitoh T, Usuki K, Taguchi J, Watanabe R, Kobayashi S, Yano S, Kanamori H, Takahashi S, and Okamoto S.</p>	<p>Effect of the order of TBI and cyclophosphamide administration on the outcome of allogeneic hematopoietic stem cell transplantation.</p>	<p>Bone Marrow Transplant.</p>	<p>Nov.50(11)</p>	<p>1476-9</p>	<p>2015</p>
<p>Ortani K, Okamoto S, Tauchi T, Saito S, Ohishi K, Handa H, Takenaka K, Gopalakrishna P, Amagasaki T, Ito K, and Akashi K.</p>	<p>A multinational open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis:Japanes e subset analysis.</p>	<p>Int J Hematol</p>	<p>Mar,101(3)</p>	<p>295-304</p>	<p>2015</p>

Saida S., Watanabe, K., Kato, I., Fujino, H., Umeda, K., Okamoto, S., Uemoto, S., Hishiki, T., Yoshida, H., Tanaka, S., Adachi, S., Niwa, A., Nakahata, T., and Heike, T.	Prognostic significance of aminopeptidase-N (CD13) in hepatoblastoma. : official journal of the Japan Pediatric Society	Pediatrics international	57	558-566	2015
Suzuki NM, Niwa A, Yabe M, Hira A, Okada C, Amano N, Watanabe A, Watanabe K, Heike T, Takata M, Nakahata T, and Saito MK	Pluripotent cell models of Fanconi anemia identify the early pathological defect in human hemoangiogenic progenitors.	Stem Cells Transl Med.	4	333-8	2015
Nemoto A., Saida S., Kato I., Kikuchi J., Furukawa Y., Maeda Y., Akahane K., Honma-Oshiro H., Goi H., Kagami K., Kimura S., Sato Y., Okabe S., Niwa A., Watanabe K., Nakahata T., Heike T., Sugita K., and Inukai T.	Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.	Mol Cancer Ther.	15	94-105	2016

Taga T, Watanabe T, Tomizawa D, Kudo K, Terui K, Moritake H, Kinoshita A, Md SI, Md HN, Md HT, Md AS, Taki T, Toki T, Ito E, Goto H, Koh K, Saito AM, Horibe K, Nakahata T, Tawa A, and Adachi S.	Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan.	Pediatr Blood Cancer.	63	248-254	2016
Takahashi H, Watanabe T, Kinoshita A, Yuza Y, Moritake H, Terui K, Iwamoto S, Nakayama H, Shimada A, Kudo K, Taki T, Yabe M, Matsushita H, Yamashita Y, Koike K, Ogawa A, Kosaka Y, Tomizawa D, Taga T, Saito AM, Horibe K, Nakahata T, Miyachi H, Tawa A, and Adachi S.	High event-free survival rate with minimum-dose-anthracycline treatment in childhood acute promyelocytic leukaemia: a nationwide prospective study by the Japanese Paediatric Leukaemia/Lymphoma Study Group.	Br J Haematol.			2016
齋藤潤、中畑龍俊	iPS細胞を使った血液疾患研究	病理と臨床	33	582-586	2015
中畑龍俊	臨床応用を目指した基礎研究 疾患モデル細胞、iPS細胞を用いた毒性評価と創薬研究 「iPS細胞を用いた疾患モデル研究(総論)」	日本臨床	37	374-380	2015

中畑龍俊	iPS細胞研究の現状と今後の臨床展開-いよいよ本格化する再生医療と創薬の世界	血液事業	38	359	2015
齋藤潤、中畑龍俊	血液・免疫疾患のiPS細胞研	月刊細胞	48	13-16	2016
中畑龍俊	iPS細胞を用いた今後の医療	長野県医学会雑誌	46	75-76	2016
Kako S, Akahoshi Y, Harada N, Nakano H, Kameda K, Ugai T, Wada H, Yamasaki R, Ishihara Y, Kawamura K, Sakamoto K, Sato M, Ashizawa M, Terasako-Saito K, Kimura S, Kikuchi M, Nakasone H, Yamazaki R, Kanda J, Nishida J, and Kanda Y.	Meta-analysis and meta-regression analysis to compare the outcomes of chemotherapy for T- and B- lineage acute lymphoblastic leukemia (ALL): The use of dexamethasone, L-asparaginase, and/or methotrexate may improve the outcome of T-lineage ALL.	Annals of Hematology	95	87-92	2016